[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368731-105":59,"doc-detail-368731-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ofd1-inhibition-induces-brcaness-to-create-a-therapeutic-vulnerability-to-parp-inhibition-in-pancreatic-cancer","OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer","","OFD1 functions as a positive regulator of BRCA1 in pancreatic cancer cells and patient specimens, where its elevated expression associates with poor prognosis. OFD1 depletion impairs homologous recombination repair (HRR) and creates synthetic lethality with PARP inhibitors. Mechanistically, OFD1 prevents DREAM complex assembly at the BRCA1 promoter by interacting with E2F4 in the cytosol, and disrupting this interaction increases E2F4 nuclear translocation and suppresses BRCA1 transcription. Targeting OFD1 synergizes with olaparib across multiple pancreatic cancer xenograft models, supporting OFD1 as a therapeutic target to induce BRCAness in BRCA-proficient disease.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ofd1-inhibition-induces-brcaness-to-create-a-therapeutic-vulnerability-to-parp-inhibition-in-pancreatic-cancer/368731/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ofd1-inhibition-induces-brcaness-to-create-a-therapeutic-vulnerability-to-parp-inhibition-in-pancreatic-cancer/368731.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is BRCAness and why does it matter for pancreatic cancer therapy?","Question",{"text":112,"@type":113},"BRCAness refers to HRR deficiency phenotypes that mimic BRCA1/2 loss, leading to sensitivity to PARP inhibitors. It matters because PARP inhibitor benefit in PDAC is limited to a small subset of patients with BRCA1/2-related risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does OFD1 inhibition affect DNA repair and PARP inhibitor response?",{"text":117,"@type":113},"OFD1 depletion impairs HRR and induces synthetic lethality with PARP inhibitors. In multiple pancreatic cancer model systems, OFD1 targeting also synergizes with olaparib.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links OFD1 to BRCA1 transcriptional regulation?",{"text":121,"@type":113},"OFD1 interacts with E2F4 in the cytosol to prevent assembly of the DREAM transcriptional repressor complex at the BRCA1 promoter. Disrupting this axis promotes E2F4 nuclear translocation and DREAM complex formation, suppressing BRCA1 expression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368731,1790195398,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Article [https://doi.org/10.1038/s41467-025-62295-8](https://doi.org/10.1038/s41467-025-62295-8)  \nOFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer  \nReceived: 1 April 2024  \n\n| Accepted: 17 July 2025 |\n| --- |\n| |\n| Check for updates |\n\nPeng Li1,4, Junjie Ye 1,4, Qian Yang1,4, Ni Wang1, Chaoyi Li1, Xiaoxiao Zou 1, Hanyan Luo1, Yi Pan1, Lingxi Jiang 2,3, Baiyong Shen 2,3 ,  \nZaiming Tang 1  & Qing Zhong 1   \nBRCAness is a homologous recombination repair (HRR) deﬁciency phenotype mimicking BRCA1/2 loss, leading to PARP inhibitor sensitivity in BRCAassociated cancers including pancreatic cancer1–7. However, how to induce BRCAness in BRCA-proﬁcient tumors remains unclear. We identify OFD1 as a positive regulator of BRCA1 in human pancreatic cancer cells and specimens, with its overexpression correlating with poor prognosis. OFD1 depletion impairs HRR and confers synthetic lethality with PARP inhibitors. Mechanistically, OFD1 interacts with E2F4 in the cytosol to prevent assembly of the transcriptional repressor DREAM complex at the BRCA1 promoter. Targeting OFD1 or disrupting its interaction with E2F4 promotes E2F4 nuclear translocation and DREAM complex formation, suppressing BRCA1 expression. OFD1 inhibition synergizes with olaparib in pancreatic cancer xenograft, spontaneous, and patient-derived xenograft models, and in other BRCA-associated cancer models. These ﬁndings reveal a mechanism of BRCA1 transcriptional regulation and highlight OFD1 as a therapeutic target to induce BRCAness in BRCA-proﬁcient pancreatic cancer.  \nPancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer globally, with a ﬁve-year survival rate of less than 20%8. Chemotherapy and surgery are currently the primary therapeutic options for PDAC, however, the low rate of early diagnosis and the high metastasis rate result in life-threatening recurrence in 80% of patients with PDAC who undergo surgical resection9,10. The most common genetic mutations associated with pancreatic cancer include KRAS, TP53, SMAD4, and CDKN2A11. Furthermore, whole-genome sequencing has identiﬁed inherited BRCA1/2 mutations as genetic risk factors for pancreatic cancer12. BRCA1 and BRCA2 play a crucial role in the DNA repair process through the HRR pathway13–16. PARP inhibitor (PARPi) was initially developed to block DNA base excision repair, which leads to the  \nconversion of single-strand nicks into double-strand breaks. Cells harboring BRCA1/2 mutations are unable to repair these DNA doublestrand breaks, ultimately resulting in programmed cell death5,17. More recently, PARPi have been shown to trap PARP1/2 proteins on DNA, thereby impairing DNA transcription and replication. In such cases, HRR is required to resolve the trapped PARP-DNA complexes. Cells with deﬁcient HRR activity fail to repair these complexes, leading to replication fork degradation and apoptosis2. As the ﬁrst drug developed based on the principle of synthetic lethality, PARPi has provided clinical beneﬁts to cancer patients with BRCA1/2 mutations18. Despite these signiﬁcant breakthroughs, the clinical utility of PARPi remains limited to a small subset of PDAC patients, ~5–7%6,19. Therefore,  \n1Institute for Translational Medicine on Cell Fate and Disease, Shanghai Ninth People’s Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai, China. 2Shanghai Key Laboratory of Pancreatic Neoplasms Translational Medicine, Research Institute of Pancreatic Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3State Key Laboratory of Systems Medicine for Cancer, Shanghai, China. 4These authors contributed equally: Peng Li, Junjie Ye, Qian Yang.  \ne-mail: [shenby@shsmu.edu.cn](shenby@shsmu.edu.cn); [zaimingtang2017@shsmu.edu.cn](zaimingtang2017@shsmu.edu.cn); [qingzhong@shsmu.edu.cn](qingzhon","cbCaipVPk8ajmbvn","https://ap.wps.com/l/cbCaipVPk8ajmbvn","pdf",6554531,18,"English","# Article summary\n## BRCAness and PARP inhibitor sensitivity\n## OFD1 as a regulator of BRCA1 and HRR\n## Mechanism involving E2F4 and DREAM complex\n## Therapeutic synergy and model validation\n## Background on PDAC and PARP inhibitor limitations","[{\"question\":\"What is BRCAness and why does it matter for pancreatic cancer therapy?\",\"answer\":\"BRCAness refers to HRR deficiency phenotypes that mimic BRCA1/2 loss, leading to sensitivity to PARP inhibitors. It matters because PARP inhibitor benefit in PDAC is limited to a small subset of patients with BRCA1/2-related risk.\"},{\"question\":\"How does OFD1 inhibition affect DNA repair and PARP inhibitor response?\",\"answer\":\"OFD1 depletion impairs HRR and induces synthetic lethality with PARP inhibitors. In multiple pancreatic cancer model systems, OFD1 targeting also synergizes with olaparib.\"},{\"question\":\"What mechanism links OFD1 to BRCA1 transcriptional regulation?\",\"answer\":\"OFD1 interacts with E2F4 in the cytosol to prevent assembly of the DREAM transcriptional repressor complex at the BRCA1 promoter. Disrupting this axis promotes E2F4 nuclear translocation and DREAM complex formation, suppressing BRCA1 expression.\"}]","OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer | PDF",1790178248,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d27102e02bb1863ab1441fd263ab62f1.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cfaa37376763ec6a90d9e65e291573aa.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e31d5033b4a32201c6147e5573ac41d.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6905718650a3c3250236fd4696fc5cf2.webp",980,1301]